Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) stock price target increased to $4.00, issued a ratings update today by Zacks Investment Research
- Updated: November 30, 2016
Boasting a price of $3.62, Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) traded -3.04% lower on the day. With the last stock price close down -15.70% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.03% over the date range. Galmed Pharmaceuticals Ltd has recorded a 50-day average of $3.67 and a two hundred day average of $4.16. Volume of trade was down over the average, with 17,503 shares of GLMD changing hands under the typical 116,164
In a report released on Wednesday November 30, 2016 Zacks Investment Research increased the stock price target of Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) to $4.00 stating a potential upside of 0.10%.
With a total market value of $0, Galmed Pharmaceuticals Ltd has with a one year low of $2.78 and a one year high of $9.70 .
A total of 5 equity analysts have released a research note on GLMD. One equity analyst rating the company a strong buy, four equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $18.20.
Brief Synopsis About Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product candidate, aramchol, is a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis (NASH). The Company's Aramchol is a conjugate of cholic acid and arachidic acid, which is a member of synthetic Fatty-Acid/Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis (NASH). Aramchol is in Phase IIb clinical trials.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.